LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)
Clinical trials for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) explained in plain language.
Never miss a new study
Get alerted when new LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) trials appear
Sign up with your email to follow new studies for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of immunotherapy, targeted drug, chemo, and radiation takes on lung cancer
Disease control Not yet recruitingThis phase 2 trial is testing a powerful combination of treatments for people with limited-stage small cell lung cancer (LS-SCLC) who have not had prior therapy. Participants will receive an immunotherapy drug (benmelstobart), an anti-angiogenic pill (anlotinib), standard chemoth…
Matched conditions: LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)
Phase: PHASE2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug cocktail aims to stop lung cancer return in Early-Stage patients
Disease control Not yet recruitingThis study tests whether combining two drugs, tislelizumab and nintedanib, can help control limited-stage small cell lung cancer after standard chemoradiation. About 20 adults with good performance status will receive this consolidation therapy. The goal is to delay cancer progre…
Matched conditions: LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)
Phase: PHASE4 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC